S
Shihuang Su
Researcher at University of Texas MD Anderson Cancer Center
Publications - 4
Citations - 409
Shihuang Su is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Interleukin 21 & T cell. The author has an hindex of 3, co-authored 4 publications receiving 332 citations.
Papers
More filters
Journal ArticleDOI
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Partow Kebriaei,Harjeet Singh,M. Helen Huls,Matthew J. Figliola,Roland L. Bassett,Simon Olivares,Bipulendu Jena,Margaret J. Dawson,Pappanaicken R. Kumaresan,Shihuang Su,Sourindra Maiti,Jianliang Dai,Branden S. Moriarity,Marie Andrée Forget,Vladimir Senyukov,Aaron F. Orozco,Tingting Liu,Jessica McCarty,Rineka Jackson,Judy S. Moyes,Gabriela Rondon,Muzaffar H. Qazilbash,Stefan O. Ciurea,Amin M. Alousi,Yago Nieto,Katy Rezvani,David Marin,Uday R. Popat,Chitra Hosing,Elizabeth J. Shpall,Hagop M. Kantarjian,Michael J. Keating,William G. Wierda,Kim Anh Do,David A. Largaespada,Dean A. Lee,Dean A. Lee,Perry B. Hackett,Richard E. Champlin,Laurence J.N. Cooper,Laurence J.N. Cooper +40 more
TL;DR: CD19-specific CAR T cells generated with Sleeping Beauty transposon/transposase platforms were safe, and may provide additional cancer control as planned infusions after HSCT, and support further clinical development of this nonviral gene therapy approach.
Journal ArticleDOI
Pre-Emptive Donor Lymphocyte Infusion with CD19-Directed, CAR-Modified T Cells Infused after Allogeneic Hematopoietic Cell Transplantation for Patients with Advanced CD19+ Malignancies
Partow Kebriaei,Stefan O. Ciurea,Mary Helen Huls,Harjeet Singh,Simon Olivares,Shihuang Su,Matthew J. Figliola,Pappanaicken R Kumar,Bipulendu Jena,Marie-Andree Forget,Sonny Ang,Rineka Jackson,Tingting Liu,Ian K. McNiece,Gabriela Rondon,Perry B. Hackett,Hagop M. Kantarjian,Dean A. Lee,Uday R. Popat,Amin M. Alousi,Betul Oran,Nina Shah,Chitra Hosing,David Marin,Katayoun Rezvani,Elizabeth J. Shpall,Richard E. Champlin +26 more
TL;DR: It is hypothesized that infusing CAR-modified, CD19-specific T-cells after HCT as a directed DLI would be associated with a low rate of GVHD, better disease control, and a less severe cytokine release syndrome since administered in a minimal disease state.
Journal ArticleDOI
Shortening the Time to Manufacture CAR+ T Cells with Sleeping Beauty System Supports T-Cell Engraftment and Anti-Tumor Effects in Patients with Refractory CD19+ Tumors
Partow Kebriaei,Helen Huls,Susan Lynn Neel,Simon Olivares,Aaron F. Orozco,Shihuang Su,Sourindra Maiti,Amy Smith,Elenanor De Groot,Hagop M. Kantarjian,Maro Ohanian,Katy Rezvani,Elizabeth J. Shpall,Richard E. Champlin,Laurence J.N. Cooper,Harjeet Singh +15 more
TL;DR: These initial data describing the infusion of SB-modified T cells with a revised extracellular domain and under reduced manufacturing time results in the detection of genetically modified T cells and anti-tumor effects in patients with relapsed/refractory ALL apparently without clinically-significant CRS.
Journal ArticleDOI
Very Rapid Production of CAR+ T-Cells upon Non-Viral Gene Transfer Using the Sleeping Beauty System
Lenka V. Hurton,Harjeet Singh,Kirsten Switzer,Tiejuan Mi,Leo G. Flores,Aaron F. Orozco,Sourindra Maiti,Shihuang Su,Amer Najjar,M. H. Huls,Partow Kebriaei,Richard E. Champlin,Laurence J.N. Cooper +12 more
TL;DR: This approach to expediting the generation of genetically modified T cells enables the administration of CAR-modified naive T cells and demonstrates that POC T cells have potent anti-tumor effects, even at a reduced CAR+ T-cell dose.